Health tech company Respiree has raised US$11.6m in Series A funding to expand its AI tools for managing disease progression across care settings.
Founded in Singapore, the company said its augmented-AI platform is designed to support clinical decision-making by automating patient monitoring, care pathway management and the delivery of medical insights.
One of its key AI models, developed during the Mayo Clinic Platform Accelerate programme, helps clinicians detect early signs of patient deterioration – including before rapid response calls or unplanned transfers to intensive care.
The model reduced false alarms while maintaining strong sensitivity.
Dr Gurpreet Singh, founder and chief executive of Respiree, said: “The digitalisation of healthcare offers a powerful opportunity to improve outcomes and efficiency – but without the right tools, it risks overwhelming care systems, especially amid workforce shortages.
“What we need is better use of data, not just more data.
“Our AI solutions enable timely interventions, reduce alarm fatigue, and support care quality.
“We’re now focused on scaling these tools to enhance the entire patient journey – from smarter triage to follow-up.”
According to Respiree, the model outperformed EPIC’s widely used deterioration index, achieving a positive predictive value of 54.9 per cent compared with 8 per cent.
Positive predictive value indicates how likely it is that a flagged case is genuinely at risk.
Respiree is currently seeking clearance from the US Food and Drug Administration to integrate the model into its platform, 1Bio.
The system combines data from electronic health records, mobile surveys, third-party devices and Respiree’s proprietary, US-patented, FDA-cleared wearable sensors to track disease trajectories over time.
Alarm fatigue occurs when staff become desensitised to frequent alerts, increasing the risk of missing critical signals.
Respiree is expanding internationally, with its technology already used in the US, Australia and across the Asia-Pacific region. It recently began a pilot partnership with Roche Diagnostics across Asia-Pacific.
The Series A funding was led by We Venture Capital and ClavystBio, with support from Adaptive Capital Partners.
Louise Warme, head of We Venture Capital, said: “We are very proud to welcome Respiree to the We VC portfolio.
“[It] stands out in the market by providing a patient monitoring AI/ML + hardware solution with incredible performance, but also unmatched understanding and execution of clinical workflow integration.”
